Adam Caar
Developer
Use this space to introduce yourself and share your professional history.
Adam Caar
Developer
Use this space to introduce yourself and share your professional history.
Adam Caar
Developer
Use this space to introduce yourself and share your professional history.
Adam Caar
Developer
Use this space to introduce yourself and share your professional history.
Case Study: Bringing the JFord Speculum Sleeve™ from Concept to FDA Clearance
The Core Problem or Opportunity
The JFord Speculum Sleeve™ was born from a clinical challenge that Dr. Jacqueline Ford had encountered repeatedly throughout her years in gynecologic practice. During routine pelvic examinations, standard vaginal speculums can be less effective in patients with larger body habitus, where redundant vaginal tissue may encroach into the examination field and limit clear visualization of the cervix. While clinicians have developed workarounds over time, there was no dedicated, commercially available solution designed specifically to address this challenge using the speculums already found in most exam rooms. The opportunity was not to replace the speculum itself, but to enhance its performance in situations where visualization can be compromised. Had the product not been developed, providers would have continued relying on improvised techniques that can increase examination difficulty and variability. The JFord Speculum Sleeve™ sought to provide a purpose-built solution for a challenge that had long been accepted as part of clinical practice. Because the device entered a regulated healthcare market, development also required navigating the FDA review process. The product ultimately received FDA clearance for sale on March 6, 2026, representing a significant milestone for both the product and the newly formed company behind it.
Who the Product Serves
The primary users of the JFord Speculum Sleeve™ are gynecologists and other women's healthcare providers performing pelvic examinations in outpatient clinical settings. Healthcare facilities purchasing the product ultimately support clinicians who require reliable visualization during routine exams. In a standard examination, a vaginal speculum is inserted and opened vertically to separate tissue and allow visual inspection of the cervix. In some patients, however, lateral tissue can move inward between the opened blades, reducing the clinician's line of sight. The device was designed to address this specific workflow challenge. It needed to: Fit onto commonly used medium and large speculums already in practice; Be inserted comfortably before the speculum was opened; Expand without interfering with normal examination technique; Create lateral displacement of tissue to help maintain the visual field. These requirements meant the product's usability was inseparable from its clinical effectiveness. The solution had to integrate naturally into established examination procedures while satisfying FDA expectations for safety and performance.
Business Context
For Ford MedTech, the JFord Speculum Sleeve™ represented more than a new product—it became the company's inaugural offering and the realization of Dr. Ford's vision to address an unmet clinical need she had witnessed firsthand. Like many startup medical technology ventures, the project operated under meaningful constraints. Budget considerations required efficient use of development resources, while regulatory timelines created pressure to maintain momentum and avoid costly delays. Ford MedTech's lean structure meant that Nexus became far more than a contract design firm. Nexus served as a trusted product realization partner, helping guide decisions across engineering, manufacturing, testing, and supplier engagement, while supporting regulatory preparation. For a first-time product company, that continuity helped transform an early concept into a commercially viable medical device.
Key Constraints
Several constraints shaped the project from the outset. Dr. Ford had previously worked with another design firm to secure intellectual property protection, establishing a patented product concept before Nexus became involved. Those early patent decisions influenced both the overall form of the device and the manufacturing approaches available to the team. The product also faced practical design challenges: - A single sleeve configuration needed to accommodate a range of medium and large speculums. - Inflatable components had to reliably maintain shape and performance during use. - Materials had to satisfy biocompatibility requirements appropriate for patient-contact devices. -Testing methods had to be developed to evaluate performance before clinical introduction. These constraints ultimately drove innovation, forcing the team to balance usability, manufacturability, regulatory requirements, and patent considerations simultaneously.
Nexus's Role
How We Were Engaged
The Core Problem or Opportunity
The JFord Speculum Sleeve™ was born from a clinical challenge that Dr. Jacqueline Ford had encountered repeatedly throughout her years in gynecologic practice. During routine pelvic examinations, standard vaginal speculums can be less effective in patients with larger body habitus, where redundant vaginal tissue may encroach into the examination field and limit clear visualization of the cervix. While clinicians have developed workarounds over time, there was no dedicated, commercially available solution designed specifically to address this challenge using the speculums already found in most exam rooms. The opportunity was not to replace the speculum itself, but to enhance its performance in situations where visualization can be compromised. Had the product not been developed, providers would have continued relying on improvised techniques that can increase examination difficulty and variability. The JFord Speculum Sleeve™ sought to provide a purpose-built solution for a challenge that had long been accepted as part of clinical practice. Because the device entered a regulated healthcare market, development also required navigating the FDA review process. The product ultimately received FDA clearance for sale on March 6, 2026, representing a significant milestone for both the product and the newly formed company behind it.